Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tucatinib in Combination With Oral Etoposide (VP16) - Trastuzumab in Patients With Metastatic HER2+ Breast Cancer After Progression Under Tucatinib-Capecitabine-Trastuzumab or Toxicity Related to Capecitabine: a Multicenter Phase II

NCT05955170 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT05955170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05955170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tucatinib in Combination With Oral Etoposide (VP16) - Trastuzumab in Patients With Metastatic HER2+ Breast Cancer After Progression Under Tucatinib-Capecitabine-Trastuzumab or Toxicity Related to Capecitabine: a Multicenter Phase II
Lead sponsor
Institut Curie
Phase
Phase 2
Overall status
Recruiting
Start date
December 19, 2023
Completion date
December 19, 2028
Enrollment
66 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer